| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jong-Min Woo, So Jung Park, Ho Il Kang, Byoung Guk Kim, Sun Bo Shim, Seung Wan Jee, Su Hae Lee, Ji Soon Sin, Chang Joon Bae, Mee Kyung Jang, Chunghee Cho, Dae Youn Hwang, Chuel Kyu Ki. Characterization of changes in global gene expression in the brain of neuron-specific enolase/human Tau23 transgenic mice in response to overexpression of Tau protein. International journal of molecular medicine. vol 25. issue 5. 2010-07-05. PMID:20372808. |
tau is a neuronal phosphoprotein responsible for the formation of the neurofibrillary tangles in alzheimer's disease. |
2010-07-05 |
2023-08-12 |
mouse |
| D Saiz-Sanchez, I Ubeda-Bañon, C de la Rosa-Prieto, L Argandoña-Palacios, S Garcia-Muñozguren, R Insausti, A Martinez-Marco. Somatostatin, tau, and beta-amyloid within the anterior olfactory nucleus in Alzheimer disease. Experimental neurology. vol 223. issue 2. 2010-07-01. PMID:19559700. |
somatostatin, tau, and beta-amyloid within the anterior olfactory nucleus in alzheimer disease. |
2010-07-01 |
2023-08-12 |
Not clear |
| Todd E Golde, Leonard Petrucelli, Jada Lewi. Targeting Abeta and tau in Alzheimer's disease, an early interim report. Experimental neurology. vol 223. issue 2. 2010-07-01. PMID:19716367. |
targeting abeta and tau in alzheimer's disease, an early interim report. |
2010-07-01 |
2023-08-12 |
Not clear |
| Todd E Golde, Leonard Petrucelli, Jada Lewi. Targeting Abeta and tau in Alzheimer's disease, an early interim report. Experimental neurology. vol 223. issue 2. 2010-07-01. PMID:19716367. |
the amyloid beta (abeta) and tau proteins, which misfold, aggregate, and accumulate in the alzheimer's disease (ad) brain, are implicated as central factors in a complex neurodegenerative cascade. |
2010-07-01 |
2023-08-12 |
Not clear |
| Kurt R Brunden, Carlo Ballatore, Alex Crowe, Amos B Smith, Virginia M-Y Lee, John Q Trojanowsk. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Experimental neurology. vol 223. issue 2. 2010-07-01. PMID:19744482. |
tau-directed drug discovery for alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. |
2010-07-01 |
2023-08-12 |
Not clear |
| Kurt R Brunden, Carlo Ballatore, Alex Crowe, Amos B Smith, Virginia M-Y Lee, John Q Trojanowsk. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Experimental neurology. vol 223. issue 2. 2010-07-01. PMID:19744482. |
the microtubule-associated protein tau forms insoluble filaments that deposit as neurofibrillary tangles (nfts) in the brains of those with alzheimer's disease (ad) and other related neurodegenerative disorders. |
2010-07-01 |
2023-08-12 |
Not clear |
| Félix Hernández, Elena Gómez de Barreda, Almudena Fuster-Matanzo, José J Lucas, Jesús Avil. GSK3: a possible link between beta amyloid peptide and tau protein. Experimental neurology. vol 223. issue 2. 2010-07-01. PMID:19782073. |
tau phosphorylation is important in alzheimer disease pathology and in other tauopathies. |
2010-07-01 |
2023-08-12 |
Not clear |
| Félix Hernández, Elena Gómez de Barreda, Almudena Fuster-Matanzo, José J Lucas, Jesús Avil. GSK3: a possible link between beta amyloid peptide and tau protein. Experimental neurology. vol 223. issue 2. 2010-07-01. PMID:19782073. |
in alzheimer disease, it has been proposed that the peptide beta amyloid promotes gsk3 activation, resulting in tau phosphorylation. |
2010-07-01 |
2023-08-12 |
Not clear |
| Félix Hernández, Elena Gómez de Barreda, Almudena Fuster-Matanzo, José J Lucas, Jesús Avil. GSK3: a possible link between beta amyloid peptide and tau protein. Experimental neurology. vol 223. issue 2. 2010-07-01. PMID:19782073. |
in this work, we review the links between beta amyloid peptide, tau protein and gsk3 that occur in familial alzheimer disease. |
2010-07-01 |
2023-08-12 |
Not clear |
| James Folwell, Catherine M Cowan, Kiren K Ubhi, Hassan Shiabh, Tracey A Newman, David Shepherd, Amritpal Mudhe. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease. Experimental neurology. vol 223. issue 2. 2010-07-01. PMID:19782075. |
abeta exacerbates the neuronal dysfunction caused by human tau expression in a drosophila model of alzheimer's disease. |
2010-07-01 |
2023-08-12 |
human |
| James Folwell, Catherine M Cowan, Kiren K Ubhi, Hassan Shiabh, Tracey A Newman, David Shepherd, Amritpal Mudhe. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease. Experimental neurology. vol 223. issue 2. 2010-07-01. PMID:19782075. |
alzheimer's disease (ad) is characterised by neurofibrillary tangles composed of hyper-phosphorylated tau, and neuritic plaques composed of misfolded amyloid peptide (abeta(42)). |
2010-07-01 |
2023-08-12 |
human |
| A Petzold, M D Chapman, S Schraen, N A Verwey, F Pasquier, S Bombois, J Brettschneider, N C Fox, C A F von Arnim, C Teunissen, Y Pijnenburg, M W Riepe, M Otto, H Tumani, P Scheltens, L Buee, M N Rosso. An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels. Experimental neurology. vol 223. issue 2. 2010-07-01. PMID:20005225. |
an unbiased, staged, multicentre, validation strategy for alzheimer's disease csf tau levels. |
2010-07-01 |
2023-08-12 |
Not clear |
| A Petzold, M D Chapman, S Schraen, N A Verwey, F Pasquier, S Bombois, J Brettschneider, N C Fox, C A F von Arnim, C Teunissen, Y Pijnenburg, M W Riepe, M Otto, H Tumani, P Scheltens, L Buee, M N Rosso. An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels. Experimental neurology. vol 223. issue 2. 2010-07-01. PMID:20005225. |
newly proposed diagnostic criteria for alzheimer's disease include cerebrospinal fluid (csf) tau levels as one core supportive criterion. |
2010-07-01 |
2023-08-12 |
Not clear |
| A Petzold, M D Chapman, S Schraen, N A Verwey, F Pasquier, S Bombois, J Brettschneider, N C Fox, C A F von Arnim, C Teunissen, Y Pijnenburg, M W Riepe, M Otto, H Tumani, P Scheltens, L Buee, M N Rosso. An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels. Experimental neurology. vol 223. issue 2. 2010-07-01. PMID:20005225. |
the published high sensitivity and specificity figures for csf tau levels in alzheimer's disease are offset by the large range of proposed cutoff values (9.6 pg/ml to 1140 pg/ml). |
2010-07-01 |
2023-08-12 |
Not clear |
| Lidia Glodzik, Susan De Santi, Kenneth E Rich, Miroslaw Brys, Elizabeth Pirraglia, Rachel Mistur, Remigiusz Switalski, Lisa Mosconi, Martin Sadowski, Henrik Zetterberg, Kaj Blennow, Mony J de Leo. Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology. Journal of Alzheimer's disease : JAD. vol 18. issue 3. 2010-06-30. PMID:19661628. |
in this study, phosphorylated tau (p-tau) and total tau (t-tau) were measured before and after 6 month treatment with memantine in 12 subjects ranging from normal cognition with subjective memory complaints, through mild cognitive impairment to mild alzheimer's disease. |
2010-06-30 |
2023-08-12 |
human |
| David B Wang, Robert D Dayton, Richard M Zweig, Ronald L Klei. Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response. Experimental neurology. vol 224. issue 1. 2010-06-28. PMID:20346943. |
neurofibrillary tangles comprised of the microtubule-associated protein tau are pathological features of alzheimer's disease and several other neurodegenerative diseases, such as progressive supranuclear palsy. |
2010-06-28 |
2023-08-12 |
rat |
| Kensaku Kasuga, Takayoshi Tokutake, Atsushi Ishikawa, Tsuyoshi Uchiyama, Takahiko Tokuda, Osamu Onodera, Masatoyo Nishizawa, Takeshi Ikeuch. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. Journal of neurology, neurosurgery, and psychiatry. vol 81. issue 6. 2010-06-23. PMID:20522869. |
differential levels of alpha-synuclein, beta-amyloid42 and tau in csf between patients with dementia with lewy bodies and alzheimer's disease. |
2010-06-23 |
2023-08-12 |
Not clear |
| Kensaku Kasuga, Takayoshi Tokutake, Atsushi Ishikawa, Tsuyoshi Uchiyama, Takahiko Tokuda, Osamu Onodera, Masatoyo Nishizawa, Takeshi Ikeuch. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. Journal of neurology, neurosurgery, and psychiatry. vol 81. issue 6. 2010-06-23. PMID:20522869. |
here the utility of quantification of alpha-synuclein, beta-amyloid42 (abeta42) and tau in the csf of patients with dlb, alzheimer's disease (ad) and other dementias was examined. |
2010-06-23 |
2023-08-12 |
Not clear |
| Yong-Whan Lim, Seung-Yong Yoon, Jung-Eun Choi, Sang-Min Kim, Hui-Sun Lee, Han Choe, Seung-Chul Lee, Dong-Hou Ki. Maintained activity of glycogen synthase kinase-3beta despite of its phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model. Biochemical and biophysical research communications. vol 395. issue 2. 2010-06-21. PMID:20362550. |
glycogen synthase kinase-3beta (gsk3beta) is recognized as one of major kinases to phosphorylate tau in alzheimer's disease (ad), thus lots of ad drug discoveries target gsk3beta. |
2010-06-21 |
2023-08-12 |
rat |
| Umesh K Jinwal, John C O'Leary, Sergiy I Borysov, Jeffrey R Jones, Qingyou Li, John Koren, Jose F Abisambra, Grant D Vestal, Lisa Y Lawson, Amelia G Johnson, Laura J Blair, Ying Jin, Yoshinari Miyata, Jason E Gestwicki, Chad A Dicke. Hsc70 rapidly engages tau after microtubule destabilization. The Journal of biological chemistry. vol 285. issue 22. 2010-06-17. PMID:20308058. |
in a group of neurodegenerative diseases, such as alzheimer disease and other tauopathies, conformational changes in tau are associated with the initial stages of disease pathology. |
2010-06-17 |
2023-08-12 |
Not clear |